We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Actinium Pharmaceuticals (ATNM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ATNM and the rest of the Medical group's stocks.
Actinium Pharmaceuticals is a member of the Medical sector. This group includes 901 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 55.88% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ATNM has returned 47.76% so far this year. Meanwhile, stocks in the Medical group have gained about 0.63% on average. As we can see, Actinium Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, which includes 170 individual stocks and currently sits at #163 in the Zacks Industry Rank. On average, stocks in this group have lost 5.50% this year, meaning that ATNM is performing better in terms of year-to-date returns.
ATNM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Actinium Pharmaceuticals (ATNM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ATNM and the rest of the Medical group's stocks.
Actinium Pharmaceuticals is a member of the Medical sector. This group includes 901 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 55.88% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ATNM has returned 47.76% so far this year. Meanwhile, stocks in the Medical group have gained about 0.63% on average. As we can see, Actinium Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, which includes 170 individual stocks and currently sits at #163 in the Zacks Industry Rank. On average, stocks in this group have lost 5.50% this year, meaning that ATNM is performing better in terms of year-to-date returns.
ATNM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.